FLT3-ITDs may provide an adequate MRD marker for nearly 25% of AML patients especially in CN-AML.27 However, whether FLT3 mutational status is an adequate marker for MRD has been questioned, given that FLT3 status can change over time.28, 29 Although a relapsed patient with emerging new clone and a patient showing shift of dominant clone were identified in this study, such alterations are not common. Here, FLT3 is linked to acute myeloid leukemia.